2019 was a ground breaking year for cannabinoid derived pharmaceuticals in Europe, with growing interest in European research into their therapeutic potential. December 2019 saw the successful fast-track approval of a cannabinoid-based epilepsy drug into the UK’s NHS.

Introducing the first Cannabinoid Derived Pharmaceuticals Summit Europe taking place in London this May. In a rapidly developing field, this meeting will provide a platform to discuss the most pressing challenges must be overcome for these therapeutics to achieve their full clinical potential.

With 20+ hours of content, interactive workshops and 5 hours+ of networking with your fellow drug developers, this is the only European conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications.

Join us as we unite experts from across large pharma, innovative biotechs, academia and solution providers to overcome all the end to end challenges which are holding back therapeutic and commercial success in cannabinoid-based drug development.